Group items tagged

North America and Europe menstrual cup market and is anticipated to remain dominant during the forecast period. The rise in the number of women population and the growth in requirement of environment friendly feminine hygiene products majorly drive the growth of the North America market. More than 50% of the women population in the U.S. is in the age group of 12-50; among which 70% use tampons.

"Nucleic Acid Testing in Europe: Market Segment Forecasts and Supplier Shares"is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years.

Europe Blow Fill Seal Technology market is anticipated to grow appreciably at rate in the forecasted period. This is attributed to the rising demand for personalized medicine, increasing focus towards consumer protection, and growing adoption of Blow Fill Seal Technology (BFS) technology in the pharmaceutical industry. Blow Fill Seal (BFS) technology is a manufacturing process used in the pharmaceutical and healthcare industries to produce small, sterile, and sealed containers for liquid or semi-solid products. It is a highly automated and efficient process that integrates container formation, filling, and sealing into a single continuous operation. Blow Fill Seal (BFS) technology is commonly used for the production of unit-dose containers for ophthalmic solutions, respiratory drugs, sterile injectables, nasal sprays, and other liquid or semi-solid pharmaceutical products.

"Microbiology Testing: Granular Analysis of the Global Market" This DataPack contains 800 tables from Venture Planning Group's new 7-country study, "Global Microbiology Testing Market: US, Europe, Japan," including supplier shares, and forecasts for over 100 tests.

Course "Supplier Management for Medical Device Manufacturers" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Supplier selection and management is one of the critical issues for medical device manufacturers. Suppliers provide materials and services to the device manufacturer, which means that they can be critical to performance and delivery of your device. Neither the FDA nor your notified body regulates your suppliers (with a few exceptions). They expect you to have an effective process to ensure your suppliers perform in the regulatory environment. How well do you understand the requirements for supplier management? Could you pass a regulatory audit or inspection without any issues? This course delivers the tools, templates, and methods to help participants implement an effective and efficient supplier management program. This two-day hands-on course provides a clear understanding of the underlying principles of supplier management. The course uses exercises to solidify understanding. In addition, the course uses FDA Warning Letters to illustrate the points and help you learn from others. As part of the practical implementation, the course includes receiving acceptance activities, outsourced processes, process validation at the suppliers' location, supplier auditing techniques, and supplier issues in management review. The course uses the Global Harmonization Task Force (GHTF) framework, but expands it to cover other issues and techniques important in effective implementation. Why should you attend: Since FDA regulations do not allow them to audit your suppliers unless they make finished medical devices, they require that you have sufficient control over them. But from time to time the FDA makes a reinterpretation of what this means. This happened within the last f 5 years, so if you supplier management program is older than that, you need to make major changes in you supp

Course "Effective and Efficient Internal and Supplier Quality System Auditing for Medical Devices" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Do you want to understand how to do efficient and effective internal and supplier audits that meet all the requirements of your external auditors, but also add value to your company? Are you confused by all the requirements and guidance documents for medical device quality management systems and are tired of wading through all the regulatory language they contain. This course is for those who will do internal or supplier audits, manage an audit process for these or other company audits. This course will provide you with an easy to understand presentation on the auditing process as well as the requirements you will need to audit under ISO 13485 and the FDA Quality System Regulation (cGMP) Both FDA Quality System Regulation (QSR) and ISO 13485 require that companies do internal audits. However, because the FDA does not look at the content of internal audits, some companies do not get feedback on the true effectiveness of their internal audit system from the FDA during FDA Inspections. ISO 13485 auditors do look at internal audits, but are most concerned that you define a process that meets the requirements of the standard and are following your process. Both require that you define Auditor training is required, but this sometimes just requires reading the company's procedure, although most external auditors will look for more than this. Do you need to train new auditors for yours medical device quality management system or to audit your suppliers? Or do you need to improve the training of your internal and supplier auditors so that they add value to these audits? If you need to do either of these, this seminar will provide this training. In addition to auditing skills and hands-on auditing exercises, this seminar will provide an ove

Clinical Research Organization for Healthcare provides clinical-study and clinical-trial support for drugs and medical devices, wherein many pharmaceuticals, biotechnology, and medical device industries having operations in the Europe Union states outsource research services to CRO to increase efficiency and improve productivity.

In this report, the global GPS Receiver market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of GPS Receiver in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India

Pulmonary Arterial Hypertension (PAH) is a disease that affects the vasculature of the heart, specifically the arteries that transport blood from the heart to the lungs. Common symptoms include heart palpitations or an irregular rhythm, chest pain, coughing, wheezing, shortness of breath, chest discomfort when breathing, and sometimes even heart failure. The cause of pulmonary hypertension is not known, but research has indicated that genetic and hormonal factors may play a role in its development. The growing prevalence of Pulmonary Arterial Hypertension (PAH) is driving the growth of the Pulmonary Arterial Hypertension (PAH) Market. According to the European Respiratory Society, PAH is a rare disease, with an estimated prevalence ranging from 10 to 52 cases per million. The growing geriatric population is again increasing the prevalence of such disease which is also projected to foster the growth of the Pulmonary Arterial Hypertension (PAH) market. According to the United nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. North America is projected to gain significant growth over the forecast period and this is attributed to the growing adoption of advanced treatment for treating pulmonary arterial hypertension. Moreover, increasing spending by the government on the healthcare sector is again augmenting the regional market growth. According to the U.S. Centers for Medicare & Medicaid Services, National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach $6.2 trillion by 2028. Reads more @ https://coherentmarketinsights-blog.blogspot.com/2021/02/increasing-global-healthcare-spending.html

Pharmaceutical drug prices are rising and contribute significantly to total health expenditure worldwide. Since 2014, prescription drug prices have increased by 33%. In 2020, global spending on prescription drugs is expected to be US$ 1.3 trillion. Increasing drug prices and consumer spending on prescription drugs are increasing the demand for the pharmacy benefit management system. The system is operated by third-party administrators who act as a link between drug manufacturers, insurance providers, and pharmacists. The system assists in reducing drug prices by negotiating with drug manufacturers and retail pharmacies. Those who are enrolled in various health schemes and those without insurance can get the benefit of the pharmacy benefit management system. The system provides medicines at a lower price than those available at retail pharmacies. To reduce rising health expenses, Japan planned to start reviewing drug prices every year instead of every two years. The move reflects growing resistance to rising drug prices worldwide. In Europe, different approaches have been implemented to regulate drug prices. In Germany, manufacturers can freely set the prices of newly developed drugs during their first year on the market. Benefit assessments are done during this year and then used in price negotiations between manufacturers and the country's representatives of statutory health insurers. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/pharmacy-benefit-management-is-integral.html

Biostimulants are natural or synthetic substances that aid in reducing the dependency on fertilizers. These substances are applied to seeds, plants, and soil in order to increase plant growth, resistance to water and abiotic stresses. Increasing global population has led to focus on boosting crop yield. According to projections by Population Reference Bureau (PRB) included in the 2018 World Population Data Sheet, the world population is expected to reach 9.9 billion by 2050, up 2.3 billion or 29% from an estimated 7.6 billion people in 2018. Moreover, according to according to Food and Agriculture Organization, worldwide food demand is expected to increase by 70% by 2050. Decrease in arable land in various regions has led to has led to various challenges in the agricultural sector. According to the study 'Will Limited Land, Water, and Energy Control Human Population Numbers in the Future', published in the journal Human Ecology, the amount of arable land available per person will decrease to 1500m² by 2050 from 4000m² in 1961. In July 2020, the government of India was expected to announce guidelines to regulate the biostimulants market in the country. Earlier, in July 2019, Europe witnessed several changes regarding definition and classification of these substances. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/increasing-global-population-and-focus.html

The global dental adhesives market is segmented on the basis of product, end user, and region. Based on product, it is divided into denture adhesives and restorative dental adhesives. Based on end user, it is bifurcated into hospitals and dental clinics. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Europe constitutes the highest market share in the global cystic fibrosis therapeutics market in 2018, followed by North America owing to the increase in incidence of cystic fibrosis. Moreover, increase in governmental support for innovation and rise in funding of projects for R&D of various cystic fibrosis drugs further fuel the market growth in this region.

The scope of #Ayurveda is huge and people are searching for qualified and experienced #BAMS doctors who are expert in Ayurveda. Although there are many #Ayurvedic #experts and practitioners of Ayurveda in #Europe but still the demand is increasing.

The veterinary CRO market is segmented into service type, animal type, indication, and region to provide a detailed assessment of the market. By service type, it is divided into clinical trials, toxicology, market authorization & regulatory support, and others. By animal type, it is bifurcated into dogs & cats. By indication, it is classified into dermatology, gastrointestinal and others. By region it is bifurcated into North America, Europe, Asia-Pacific and LAMEA